NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
521 Borås

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 302 3.2% 27 0.3% 8 0.1% . . 1 0.0% 7 0.1% 9147 96.4% 9492 100.0%
ASCUS 386 23.4% 156 9.5% 46 2.8% 1 0.1% 1 0.1% 12 0.7% 1047 63.5% 1649 100.0%
LSIL 139 25.2% 130 23.6% 54 9.8% . . . . 4 0.7% 225 40.8% 552 100.0%
Atypical glandular cells/AGC 21 43.8% . . 4 8.3% 1 2.1% 3 6.3% . . 19 39.6% 48 100.0%
Unclear atypia 1 50.0% . . . . . . . . . . 1 50.0% 2 100.0%
ASC-H 31 23.5% 26 19.7% 62 47.0% . . 1 0.8% . . 12 9.1% 132 100.0%
HSIL 11 5.2% 19 9.0% 161 75.9% 4 1.9% 8 3.8% . . 9 4.2% 212 100.0%
Suspected Adenocarcinom 2 25.0% 1 12.5% . . . . 2 25.0% . . 3 37.5% 8 100.0%
Malignant tumor with unclear origin . . . . . . . . 1 100.0% . . . . 1 100.0%
Squamous cell cancer 1 20.0% . . 1 20.0% . . 3 60.0% . . . . 5 100.0%
Totalt 894 7.4% 359 3.0% 336 2.8% 6 0.0% 20 0.2% 23 0.2% 10463 86.5% 12101 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category Cancer:
M80413, M80703, M81403, M82003, M83803, M84006, M84603